Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP: DMTTF )

0.0530 UNCHANGED
Streaming Delayed Price Updated: 2:30 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Small Pharma Inc

< Previous 1 2 3 4 5 6 Next >
EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion
This is the third article of a three-part series, you can find the first and 
Via Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll... 
Via Benzinga
Small Pharma Inc: Positive Clinical Data For Major Depressive Disorder, Upcoming Virtual Roundtable
Short-acting psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) shared positive outcomes from its Phase 2a study of SPL026, the first placebo-controlled trial of the DMT-based short-duration... 
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial
Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy. 
Via Benzinga
Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents
After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc. 
Via Benzinga
Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings
Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major... 
Via Benzinga
Comparing Psychedelics' Administration Routes: Are Intramuscular Injections More Effective Than Intravenous?
Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) has dosed the first patient in its Phase 1 clinical trial assessing intramuscular (IM) versus intravenous (IV) administration of its... 
Via Benzinga
Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More
Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries 
Via Benzinga
This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage
Short-acting psychedelics biotech company Small Pharma Inc. 
Via Benzinga
Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing
Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors... 
Via Benzinga
How Certain Psychedelics Produce Brain And Behavior Changes: UCL Leads New Study
The University College London (UCL) is conducting a new research project called “Understanding Neuroplasticity Induced by Tryptamines (UNITy)” aimed at assessing brain changes and neuroplasticity... 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 23, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 8, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14 
Via Benzinga
Compass Pathways, Allied Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 3, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27 
Via Benzinga
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS: 
Via Benzinga
This Novel Short-Acting Psychedelic Compound Is Ready For First Phase 1 Clinical Try-Out
Small Pharma Inc. 
Via Benzinga
Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 3.00% at $0.87 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.39% at $0.18 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 25, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.24% at $10.39 
Via Benzinga
Allied, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 10.21% at $0.53 
Via Benzinga
This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More
Short-acting psychedelics biotech firm Small Pharma Inc. 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 18, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 15.76% at $0.14 
Via Benzinga
Small Pharma's Q2 2023 Financial Results, 'Ultra Short-Acting Psychedelic Program' Underway
Small Pharma Inc. (OTCQB: DMTTF), a biotech company developing short-acting psychedelic-assisted therapies for diverse mental health disorders, reported its financial results for the three and six... 
Via Benzinga
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.12% at $0.12 
Via Benzinga
Numinus Wellness, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.61% at $0.12 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 6, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 45.41% at $0.22 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.